Product Data Sheet

Meldonium

Cat. No.: HY-B1836 CAS No.: 76144-81-5 Molecular Formula: $C_6H_{14}N_2O_2$ Molecular Weight: 146.19

Target: Mitochondrial Metabolism Pathway: Metabolic Enzyme/Protease

Powder Storage:

4°C 2 years

3 years

-80°C In solvent 2 years

-20°C

-20°C 1 year

$$N^{\dagger}N$$

SOLVENT & SOLUBILITY

In Vitro

H₂O: 50 mg/mL (342.02 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	6.8404 mL	34.2021 mL	68.4041 mL
	5 mM	1.3681 mL	6.8404 mL	13.6808 mL
	10 mM	0.6840 mL	3.4202 mL	6.8404 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 100 mg/mL (684.04 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description Meldonium (MET-88) functions as a cardioprotective agent by competetively inhibiting γ-butyrobetaine hydroxylase (BBOX) and carnitine/organic cation transporter type 2 (OCTN2). Mildronate (Meldonium) exhibits IC $_{50}$ values of 34-62 μ M for human recombinant BBOX and an EC₅₀ of 21 µM for human OCTN2. Meldonium is a fatty acid oxidation inhibitor^{[1][2]}.

IC50: 34-62 μM (human recombinant BBOX). IC₅₀ & Target

EC50: 21 μM (human OCTN2).

In Vitro Meldonium (20-40 μM; 24 h) ameliorates lung injury by targeting PFKP to regulate glycolysis, which promotes Nrf2

translocation from the cytoplasm to the nucleus to alleviate oxidative stress and mitochondrial damage under hypoxic

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[3]

Cell Line:	Rat alveolar type II epithelial RLE-6TN cells in hypoxia incubator			
Concentration:	20, or 40 μM			
Incubation Time:	24 h			
Result:	Significantly decreased the mRNA expression of PFKP, PDK1, and PKM2 compared with the hypoxia group.			
Western Blot Analysis ^[3]	Western Blot Analysis ^[3]			
Cell Line:	Rat alveolar type II epithelial RLE-6TN cells in hypoxia incubator			
Concentration:	20, or 40 μM			
Incubation Time:	24 h			
Result:	Significantly reduced the protein expression of PFKP, PKM2, and LDHA.			

CUSTOMER VALIDATION

- J Pharmaceut Biomed. 2020, 113870.
- J Anim Sci. 2022 Mar 5;skac069.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Daohui Wang, et al. Meldonium Ameliorates Hypoxia-Induced Lung Injury and Oxidative Stress by Regulating Platelet-Type Phosphofructokinase-Mediated Glycolysis. Front Pharmacol. 2022 Apr 5:13:863451.
- [2]. Dambrova M, et al. Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity. Pharmacol Res. 2016 Nov;113(Pt B):771-780.
- [3]. Jolanta Pupure, et al. Neuroprotective properties of mildronate, a mitochondria-targeted small molecule. Neurosci Lett. 2010 Feb 12;470(2):100-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA